Colorectal cancer (CRC) screening, effective for early detection of CRC, was recently implemented by the Hong Kong government using the quantitative Fecal Immunochemical Test (FIT). However, consistently low participation rates and heavy reliance on colonoscopy for CRC screening has created a substantial burden on the healthcare system.
This study examined the feasibility, acceptability, and satisfaction of utilizing the novel non-invasive biomarker test Colotect for early detection of CRC.
In-depth, qualitative telephone interviews were conducted with 16 participants (≥ 50 years old) who were eligible for the government CRC screening program. Participants were recruited via community health centres in Hong Kong between July and August 2022. The Consolidated Framework for Implementation Research (CFIR) was used to prepare the interview guide exploring the perceptions, attitudes, and barriers to using Colotect. The data collected was categorized into eight themes corresponding to the CFIR interventional characteristics domain, including intervention sources, evidence strength & quality, relative advantage, adaptability, complexity, design quality and packaging, and cost.
Overall, participants reflected positive attitudes and perceptions toward Colotect use, along with identifying difficulties associated with its use. Modifications to test kits were proposed corresponding to the issues identified. In summary, this study demonstrated the feasibility and acceptability of using Colotect in CRC screening program. Future studies should examine the applicability, acceptability, efficiency, and cost-effectiveness of the test in real-world settings.